Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Tillman Pearce"'
Autor:
Didier Scherrer, Noel Barrett, Luc Teyton, Tillman Pearce, Josianne Nitcheu, Philippe Pouletty, Julien Santo, Hartmut J. Ehrlich
Publikováno v:
Molecular Cancer Therapeutics. 21:1788-1797
Immune checkpoint blockers (ICB) provide a promising approach to antitumor immunotherapy through blockade of immunosuppressive pathways. The synthetic glycolipid, ABX196, is a potent stimulator of invariant natural killer T cells (iNKT), a small subs
Autor:
Hartmut J. Ehrlich, Julien Santo, Philippe Pouletty, Josianne Nitcheu, Tillman Pearce, Luc Teyton, Noel Barrett, Didier Scherrer
Supplementary Figure from Demonstration of the Antitumor Activity of the iNKT Agonist ABX196, a Novel Enhancer of Cancer Immunotherapy, in Melanoma and Hepatocarcinoma Mouse Models
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::756179482cb9b7fcd36a3727c5756534
https://doi.org/10.1158/1535-7163.22523904.v1
https://doi.org/10.1158/1535-7163.22523904.v1
Autor:
Hartmut J. Ehrlich, Julien Santo, Philippe Pouletty, Josianne Nitcheu, Tillman Pearce, Luc Teyton, Noel Barrett, Didier Scherrer
Supplementary Data from Demonstration of the Antitumor Activity of the iNKT Agonist ABX196, a Novel Enhancer of Cancer Immunotherapy, in Melanoma and Hepatocarcinoma Mouse Models
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::609130139a65ecaaa5d286825fc3a9af
https://doi.org/10.1158/1535-7163.22523910.v1
https://doi.org/10.1158/1535-7163.22523910.v1
Autor:
Richard B. Lock, Malcolm A. Smith, Beverly A. Teicher, Tillman Pearce, Chi-Sheng Shia, Charles G. Mullighan, Kathryn G. Roberts, Komal S. Rathi, Donald Jung, Fanying Meng, Yuelong Guo, Stephen W. Erickson, Chelsea Mayoh, Narimanne El-Zein, Cara E. Toscan, Zhaohui Gu, Lisa McDermott, Connor D. Jones, Tara Pritchard, JianXin Duan, Kathryn Evans
Purpose:OBI-3424 is a highly selective prodrug that is converted by aldo-keto reductase family 1 member C3 (AKR1C3) to a potent DNA-alkylating agent. OBI-3424 has entered clinical testing for hepatocellular carcinoma and castrate-resistant prostate c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e1054e7a9f8ca25f82d9d09add67f38
https://doi.org/10.1158/1078-0432.c.6527832.v1
https://doi.org/10.1158/1078-0432.c.6527832.v1
Autor:
Luke S McLean, Tessa A Morris, Ann Gramza, Stephen Liu, Saad A. Khan, A. Dimitrios Colevas, Tillman Pearce, Danny Rischin
Publikováno v:
Investigational New Drugs. 40:782-788
Publikováno v:
Cancer Research. 82:P5-08
Cancer cells may be differentiated from normal cells by the surface expression of unusual glycosylation patterns: tumor-associated carbohydrate antigens (TACAs) may be expressed as membrane-bound glycoproteins or glycolipids. Differential expression
Autor:
Luke S, McLean, Tessa A, Morris, Ann, Gramza, Stephen, Liu, Saad A, Khan, A Dimitrios, Colevas, Tillman, Pearce, Danny, Rischin
Publikováno v:
Investigational new drugs. 40(4)
Tarloxotinib, a hypoxia-activated prodrug of an irreversible pan-ErbB tyrosine kinase inhibitor, represents a novel therapeutic which exploits the tumor-specific hypoxic environment as a mechanism for tumor-specific targeting. This study evaluated th
Publikováno v:
Future oncology (London, England). 18(1)
Glycans, chains of sugar molecules found conjugated to cell proteins and lipids, contribute to their growth, movement and differentiation. Aberrant glycosylation is a hallmark of several medical conditions including tumorigenesis. Glycosphingolipids
Autor:
Narimanne El-Zein, Fanying Meng, Komal S. Rathi, Stephen W. Erickson, Chelsea Mayoh, Yuelong Guo, Kathryn Evans, Connor D. Jones, Cara E. Toscan, Tillman Pearce, Charles G. Mullighan, Richard B. Lock, Jian-Xin Duan, Donald Jung, Kathryn G. Roberts, Zhaohui Gu, Malcolm A. Smith, Lisa McDermott, Chi-Sheng Shia, Beverly A. Teicher, Tara Pritchard
Publikováno v:
Clin Cancer Res
Purpose: OBI-3424 is a highly selective prodrug that is converted by aldo-keto reductase family 1 member C3 (AKR1C3) to a potent DNA-alkylating agent. OBI-3424 has entered clinical testing for hepatocellular carcinoma and castrate-resistant prostate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12232e5a1100ba377a116eb067dda2f7
https://europepmc.org/articles/PMC6635081/
https://europepmc.org/articles/PMC6635081/
Autor:
Eric Kipnis, Michel Wolff, Jean-Marie Forel, Antoine Andremont, Jean-Luc Diehl, Denis Garot, Alexandre Mebazaa, Anthony Dugard, Bruno François, Geoffrey Yarranton, Alan Jacobs, Samir Jaber, Benoit Misset, Tillman Pearce, Charles-Edouard Luyt, Jean-Yves Fagon, Marie-Cécile Ploy, Jean Chastre
Publikováno v:
Critical Care Medicine. 40:2320-2326
Objective:The type III secretion system is an important Pseudomonas aeruginosa-virulence determinant in animal models of infection and in humans. Antibody-mediated inhibition of the PcrV protein, an essential component of this system, might abrogate